David Olmos, MBBS, MSc, PhD, discusses research presented at the ASCO 2023 Annual Meeting assessing outcomes with first-line novel hormonal therapy or taxane therapy in metastatic castration-resistant prostate cancer based on patients' BRCA/HRR status.
"The overall survival, Kaplan Meier curves, are maintained with a hazard ratio of 0.79 for the intent-to-treat patient population of lenvatinib/pembrolizumab versus sunitinib," said Thomas E. Hutson, DO, PharmD, FACP.
"Our research focused on the outcomes at 6 months, [and we] were looking at disease recurrence and hernia occurrence," says Jennifer Nguyen.
"About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels," says Praveen Thumbikat, DVM, PhD.
“There are a lot of social determinants of health as it relates to urge urinary incontinence,” says Joseph Kim, MD.
"Here, we've lowered the age to initiate screening to 45 to 50 years," says Badrinath R. Konety, MD, MBA.
"Even though most urologists who do retroperitoneal surgery do it for posterior tumors, you actually can do it equally well with as equally good success for an anterior tumor," says Michael D. Stifelman, MD.
"Our main finding was that participants who experienced food insecurity in the past year were at 55% increased odds of reporting at least 1 episode of urge urinary incontinence in the past month, compared with those who have not experienced food insecurity," says Joseph Kim, MD.
"I think there's a lot of interest now on intraoperative navigation," says Jihad Kaouk, MD.
“The take-home message is that as a practicing urologist, you should be treating genitourinary syndrome of menopause and giving any woman over 45 vaginal hormones, whether in the form of vaginal estrogen or vaginal DHEA,” says Rachel S. Rubin, MD.
“We really wanted to give the general urologist the tools to go back to the clinic the next day and say, "I know how to prescribe this. I know where to prescribe it. I know the cheapest options. I know the best deals around and I know how to talk to patients about the risks and the benefits,” says Rachel S. Rubin, MD.
The data were presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
“The purpose of health care is to provide health care. And...the more we can focus on that, the more we can leverage the hope that I do think that we have,” says Colin P. West, MD, PhD.
"One of the factors that goes into why transperineal [biopsies] aren't performed more readily in the US is lack of exposure," says Jim C. Hu, MD, MPH.
“It's a challenge to get funding for these types of studies, and also to have the infrastructure to carry out a lot of these big studies. But there's no question that we need more data,” says Rachel S. Rubin, MD.
“Approaching wellbeing is a shared responsibility,” says Colin P. West, MD, PhD.
"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.
“Those who were on this vaginal DHEA had a huge decrease in the prevalence of urinary tract infections in the 1 year after getting the prescription,” says Rachel S. Rubin, MD.
"We have to be intentional in order to design our trials so that we have a better participation of those groups," says Larissa V. Rodriguez, MD.
"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.
“We need to experience fairness and respect, and we need to see that our individual values align with the values of our organizations, and of our health care system as a whole,” says Colin P. West, MD, PhD.
"What we found is that AI+ score using continuous variables had the highest predictive ability of all oncologic outcomes that were measured," says Nour Abdallah, MD.
"A lot to be done in terms of moving PARP inhibitors earlier. Is that safe? Where do we get the most bang for our buck? And does the therapy have to be indefinite?" says Ashley E. Ross, MD, PhD.
“To convince the doctors pre pandemic of telemedicine was pretty difficult, but now we know that telemedicine works and the physicians are embracing it,” says Lisa J. Finkelstein, DO, FACOS.
"This study looks at comparing BCG, which is our classic mainstay in the treatment of high-risk non-muscle–invasive bladder cancer to intravesical gemcitabine-docetaxel," says Diana Magee, MD.
"When it comes to BPH therapy, we've seen a lot of innovation when it comes to the therapeutics; the diagnostics have been a tiny bit behind," says Bilal Chughtai, MD.
“We need to continue to advocate for the patient,” says Arthur L. Burnett II, MD, MBA.
“Resilience isn't just about being able to bounce back; it's about being able to bounce back better,” says Colin P. West, MD, PhD.
"Because we don't have calibration data on Black, or Hispanic, or Asian men in many of these risk tools, we don't know the impact of these tools as screening tests," says Adam Murphy, MD, MBA, MSCI.
“I think, overall, nomograms are a really powerful tools just because there are so many different clinical variables that we consider when we talk to patients about whether to proceed with prostate biopsy,” says Eric Li, MD.
